CBT-295

CAT: 0931-MF-0122571-01Size: 10 mgDry Ice: NoHazardous: No
CAT#:0931-MF-0122571-01Size:10 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Target
Interleukin|||TGF-beta/Smad
Related Pathways
Immunology/Inflammation|||Stem Cells
Bioactivity
CBT-295, an orally active autotaxin (ATX) inhibitor, effectively decreases inflammatory cytokines including TGF-?, TNF-?, and IL-6, along with the bile duct proliferation marker CK-19, and ameliorates liver fibrosis. The compound's ability to reverse liver fibrosis contributes to lowered ammonia levels in the blood and brain, which in turn reduces ammonia-induced neuroinflammation. CBT-295 shows potential for the study of liver cirrhosis and related encephalopathy.
Molecular Formula
C18H20ClN3O
Molecular Weight
329.82
Shipping Conditions
Cool pack
Storage Temperature
-20°C

Related Products

CatalogName
MF-0116430-01ICG-CBT
MF-0126792-01QMT-CBT
MF-0043016-01ABD-295
MF-0111255-01PRL-295
MF-0062356-01AK-295
MF-0135937-01Tissue Factor Protein, Human, Recombinant (aa 1-295, His)
MF-0131463-01TIM-1/KIM-1/HAVCR1 Protein, Human, Recombinant (aa 21-295, His)
MF-0150370-01CBTF sodium
MF-0033693-01ONO-2952
MF-0022669-01JMV 2959

Alternative Products

CatalogName
HY-169004-01CBT-295
HY-D2247ICG-CBT
HY-P10674QMT-CBT
111990Anti CBT (cannabicitran) cannabitriol Pab
ABC-TC500SSF-295
HY-119378-01AK 295
HY-111248ABD-295
HY-171035-01PRL-295
4322/2JH 295
TRC-T012750-100MGTCV 295

Popular Products